Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients [see comments]

Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients [see comments]

J Hum Virol. 1998 May-Jun;1(4):293-8. Unique Identifier : AIDSLINE MED/99211158
Gringeri A; Santagostino E; Muca-Perja M; Mannucci PM; Zagury JF; Bizzini B; Lachgar A; Carcagno M; Rappaport J; Criscuolo M; Blattner W; Burny A; Gallo RC; Zagury D; Hemophilia and Thrombosis Center Angelo Bianchi Bonomi, IRCCS; Maggiore Hospital, Milan, Italy. hemophilia_ctr@polic.cilea.it

Abstract: OBJECTIVES: To antagonize the deleterious effects of the HIV-1 toxin extracellular Tat on uninfected immune cells, we developed a new strategy of anti-HIV-1 vaccine using an inactivated but immunogenic Tat (Tat toxoid). Tat toxoid has been assayed for safety and immunogenicity in seropositive patients. METHOD: The phase I vaccine clinical trial testing Tat toxoid preparation in Seppic Isa 51 oil adjuvant was performed on 14 HIV-1-infected asymptomatic although biologically immunocompromised individuals (500-200 CD4+ cells/mm3). RESULTS: Following as many as 8 injections, no clinical defects were observed. All patients exhibited an antibody (Ab) response to Tat, and some had cell-mediated immunity (CMI) as evaluated by skin test in vivo and T-cell proliferation in vitro. CONCLUSION: These results provide initial evidence of safety and potency of Tat toxoid vaccination in HIV-1-infected individuals.

Keywords: CLINICAL TRIAL CLINICAL TRIAL, PHASE I JOURNAL ARTICLE Acquired Immunodeficiency Syndrome/*IMMUNOLOGY/THERAPY/VIROLOGY Adult AIDS Vaccines/ADVERSE EFFECTS/*IMMUNOLOGY/THERAPEUTIC USE Comparative Study CD4 Lymphocyte Count Disease Progression Female Follow-Up Studies Gene Products, tat/ADVERSE EFFECTS/*IMMUNOLOGY/THERAPEUTIC USE Human HIV Antibodies/IMMUNOLOGY HIV Core Protein p24/IMMUNOLOGY HIV-1/*CHEMISTRY/IMMUNOLOGY Immunocompromised Host Male Pilot Projects
Comment in: J Hum Virol 1998 May-Jun;1(4):249-50
990730
A9971143

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .